Side Effects of Naltrexone
Naltrexone is generally well-tolerated with the most common side effects being nausea (10-13.7%), headache (7%), dizziness (4%), nervousness (4%), fatigue (4%), and insomnia (3%), while the most serious concern is dose-related hepatotoxicity at doses above 50 mg/day and the risk of precipitated opioid withdrawal in patients not completely free of opioids 1.
Common Adverse Effects (>2% incidence)
When used for alcohol use disorder at standard doses (50 mg/day), the following adverse effects occur most frequently 1:
- Gastrointestinal: Nausea (10%), vomiting (3%), abdominal pain/cramps
- Neurological: Headache (7%), dizziness (4%), somnolence (2%)
- Psychiatric: Nervousness (4%), anxiety (2%), insomnia (3%)
- General: Fatigue (4%)
In opioid addiction treatment, adverse reactions occurring in >10% of patients include difficulty sleeping, anxiety, nervousness, abdominal pain/cramps, nausea/vomiting, low energy, joint and muscle pain, and headache 1.
Serious Adverse Effects Requiring Monitoring
Hepatotoxicity (Most Critical)
At doses 5-fold higher than the standard 50 mg/day (i.e., 300 mg/day), naltrexone causes hepatocellular injury in approximately 19% of patients 1. At standard doses for alcohol use disorder or opioid blockade, hepatotoxicity is less common but still requires monitoring 2. The 2022 AGA guidelines emphasize that vital signs and liver function should be monitored in patients treated with naltrexone-bupropion combinations 2.
Key clinical considerations:
- Transaminase elevations typically occur after 3-8 weeks of treatment
- Patients are generally clinically asymptomatic
- Liver enzymes return to baseline within weeks after discontinuation
- Dose reduction required in moderate-to-severe hepatic impairment (maximum 1 tablet daily) 2
Precipitated Opioid Withdrawal (Life-Threatening)
Naltrexone can precipitate severe withdrawal reactions in patients not completely free of exogenous opioids 1. This is the most dangerous acute complication and requires:
- Verification that patients are opioid-free for 7-10 days before initiation
- Discontinuation before any procedures requiring opioid analgesia (e.g., endoscopies with fentanyl) 2
- Avoidance in patients requiring short-term or long-term opioid therapy
Neuropsychiatric Effects
Depression and suicidal ideation occur at similar rates in naltrexone-treated patients (0-15% depression, 0-1% suicide attempts) compared to placebo (0-17% depression, 0-3% suicide attempts) 1. Although no causal relationship is established, naltrexone does not reduce suicide risk in patients with alcohol use disorder 1.
Additional psychiatric effects include 1:
- Depression, paranoia, confusion, disorientation
- Hallucinations (visual hallucinations reported in case reports) 3
- Nightmares, bad dreams
- Restlessness, agitation
Seizure Risk
When combined with bupropion (naltrexone-bupropion ER), there is lowered seizure threshold. Avoid in patients with epilepsy and use with caution in those with seizure history 2.
Less Common Adverse Effects (<10% incidence)
Cardiovascular 1:
- Increased blood pressure (requires monitoring)
- Palpitations, tachycardia
- Edema, phlebitis
Gastrointestinal 1:
- Loss of appetite, diarrhea, constipation
- Excessive gas, hemorrhoids
Musculoskeletal 1:
- Joint and muscle pain
- Tremors, twitching
Genitourinary 1:
- Delayed ejaculation, decreased potency
- Changes in sexual interest
Dermatologic 1:
- Skin rash, pruritus, oily skin
Rare but Notable Adverse Effects
Recent pharmacovigilance data from the FAERS database identified additional signals not mentioned in the original drug label 4:
- Restless legs syndrome
- Eosinophilic pneumonia
- Otolithiasis
Postmarketing surveillance has also reported idiopathic thrombocytopenic purpura and vision abnormalities 1.
Withdrawal-Like Symptoms
A small fraction of patients may experience an opioid withdrawal-like symptom complex consisting of tearfulness, mild nausea, abdominal cramps, restlessness, bone or joint pain, myalgia, and nasal symptoms 1. This may represent unmasking of occult opioid use or symptoms directly attributable to naltrexone.
Special Population Considerations
Renal impairment: Reduce dose by 50% in moderate-to-severe renal impairment; avoid in end-stage renal disease 2
Hepatic impairment: Maximum 1 tablet daily in moderate-to-severe hepatic impairment 2
Young adults (<24 years): Increased monitoring for neuropsychiatric adverse effects and suicidal thoughts when combined with bupropion 2
Clinical Pitfalls to Avoid
- Never initiate naltrexone without confirming opioid-free status for 7-10 days - this prevents life-threatening precipitated withdrawal
- Hold naltrexone before procedures requiring opioid analgesia - the opioid antagonism will reduce analgesic efficacy
- Monitor liver function tests - particularly in the first 3-8 weeks of therapy
- Screen for uncontrolled hypertension - naltrexone-bupropion combinations should be avoided in these patients 2
- Avoid MAO inhibitors - contraindicated within 14 days of naltrexone-bupropion use 2
Tolerability Profile
Most adverse events occur early in therapy and are transient 1. In alcohol use disorder trials, only 5 of 93 patients (5.4%) discontinued naltrexone due to nausea 1. A Spanish cohort study of 198 patients found that 39.1% experienced adverse events, but only 3.6% were considered severe 5. Low-dose naltrexone (4.5 mg daily) for chronic pain showed 32% of patients reporting adverse effects including vivid dreams, drowsiness, dizziness, and nausea 6.